Feed excerpt — reported by STAT News
Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →